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Abstract
Rocaglates are natural products that inhibit protein synthesis in eukaryotes and exhibit anti-
neoplastic activity. In vitro biochemical assays, affinity chromatography experiments coupled with 
mass spectrometry analysis, and in vivo genetic screens have identified eukaryotic initiation factor 
(eIF) 4A as a direct molecular target of rocaglates. eIF4A is the RNA helicase subunit of eIF4F, a 
complex which mediates cap-dependent ribosome recruitment to mRNA templates. The eIF4F 
complex has been implicated in tumor initiation and maintenance through elevated levels or 
increased phosphorylation status of its cap-binding subunit, eIF4E, thus furthering the interest 
towards developing rocaglates as anti-neoplastic agents. Recent experiments have indicated that 
rocaglates also interact with prohibitins (PHB) 1 and 2; proteins implicated in c-Raf-MEK-ERK 
signaling. Since increased ERK signaling stimulates eIF4E phosphorylation status, rocaglates are 
also expected to inhibit eIF4E phosphorylation status, a point that has not been thoroughly 
investigated. It is currently unknown whether the effects on translation observed with rocaglates 
are solely through eIF4A inhibition or also a feature of blocking eIF4E phosphorylation. Here, we 
show that rocaglates inhibit translation through an eIF4E-phophorylation independent mechanism.
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INTRODUCTION
Rocaglates are a family of natural products characterized by a common cyclopenta[b]furan 
skeleton exclusively found in the Aglaia genus of the Meliaceae family of angiosperms (1). 
Many members of this family are potent inhibitors of translation initiation and exhibit single 
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agent anti-neoplastic activity in pre-clinical cell and mouse models (2–4) as well as the 
ability to modulate chemo-responsiveness (5–9). A significant body of evidence indicates 
that these compounds inhibit translation initiation by disabling eIF4F and interfering with 
ribosome recruitment to mRNA templates (2, 5, 9).
eIF4F is a hetero-trimeric complex consisting of eIF4E, a cap-binding protein; eIF4A, the 
RNA helicase target of rocaglates; and eIF4G, a large scaffolding protein. eIF4F is required 
to unwind cap-proximal secondary structure within the mRNA 5' untranslated region (UTR) 
as a prelude to 43S pre-initiation complex recruitment. Of all the initiation factors, eIF4E is 
the least abundant (10, 11) and mRNAs must compete for the limiting amounts of eIF4F 
during the initiation process. One determinant of competitive efficiency is the presence of 
structural barriers (e.g. stem-loop structures, protein-RNA interactions) within the mRNA 5' 
UTR, with elevated levels associated with poorly initiating mRNAs. Consequently, 
translation of these weaker mRNAs is most affected upon eIF4F inhibition, and hence by 
rocaglates (2, 12–14).
eIF4A is an abundant factor that exists as a free form (eIF4Af) or as part of the eIF4F 
complex (eIF4Ac). Biochemical assays using recombinant eIF4A (2, 5, 9), affinity 
chromatography experiments using immobilized epi-silvestrol (15), and chemogenomic 
profiling in yeast (16) have identified eIF4A as a predominant target of rocaglates. 
Rocaglates are thought to restrict efficient recycling of eIF4A through the eIF4F complex by 
increasing non-specific RNA binding of eIF4A (Fig. 1A) (8).
An alternative mechanism of rocaglate activity on translation initiation has been proposed 
based on their interactions with prohibitins (PHB) 1 and 2 (17). PHB1/2 are involved in a 
wide variety of cellular processes, including activation of the MAPK signaling cascade 
through direct interaction with c-RAF (18). In the presence of rocaglates, the PHB1/2:c-
RAF interaction is inhibited, leading to dampened signaling through MEK and ERK 1/2 
(17). Since MNK are activated by ERK signaling and phosphorylate eIF4E on S209, 
rocaglates are expected to inhibit eIF4E S209 phosphorylation. However, the effect of 
rocaglates on eIF4E phosphorylation status has yet to be assessed. If correct, this mechanism 
of action would have profound consequences on our understanding of the anti-neoplastic 
effects of these compounds since eIF4E phosphorylation is essential to its oncogenic activity 
(19, 20). As well, transcriptome-wide studies attributing alterations in mRNA translational 
efficiency to eIF4A inhibition by rocaglates would have to be re-interpreted if inhibition of 
eIF4E phosphorylation was a significant biological property of rocaglates (12, 13).
However, there are several lines of evidence inconsistent with inhibition of eIF4E 
phosphorylation contributing to the biological activity of rocaglates. Firstly, rocaglates are 
potent inhibitors of eIF4A-dependent translation in vitro where RAS/MEK/ERK signaling is 
not maintained (5). Secondly, rocaglates have been shown to inhibit encephalomyocarditis 
(EMC) IRES-driven translation (5), an event that is eIF4A, but not eIF4E, dependent (21). 
Thirdly, rocaglates are potent inhibitors of global cap-dependent translation (2, 5), whereas 
loss of eIF4E S209 phosphorylation leads to more selective inhibition of mRNA translation 
(20, 22–24). It therefore remains an open question as to whether the reported suppression of 
RAS/MEK/ERK signaling by rocaglates represents an essential feature of these compounds. 
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Herein, we report that the biological activity of rocaglates cannot be explained by 
modulation of eIF4E phosphorylation.
MATERIALS AND METHODS
General Methods and Reagents
Jurkat (in 2002) and NIH/3T3 (in 2005) cells were obtained from the American Type 
Culture Collection (ATCC). Mnk1+/+Mnk2+/+ and Mnk1−/−Mnk2−/− MEFs were obtained 
from Dr. Nahum Sonenberg in 2010 (McGill University, Montreal, Quebec, Canada). RAS-
transformed NIH/3T3 cells were generated by infection with pBABE-Puro.H-Ras(V12) in 
2015. Cells lines were not further authenticated. Jurkat, NIH/3T3, RAS-transformed NIH/
3T3, and Mnk1+/+Mnk2+/+ and Mnk1−/−Mnk2−/− MEFs (Mouse Embryonic Fibroblasts) 
were grown in RPMI 1640 and DMEM supplemented with 10% FBS and 100 U/ml 
penicillin/streptomycin at 37°C and 5% CO2. Cell extracts were prepared in lysis buffer (20 
mM HEPES [pH 7.5], 150 mM NaCl, 1% Triton-X100, 10% glycerol, 1 mM EDTA, 10 mM 
tetrasodium pyrophosphate, 100 mM NaF, 17.5 mM β-glycerophosphate, 1mM PMSF, 4 
μg/ml aprotinin, 2 μg/ml leupeptin, 2 μg/ml pepstatin). Extracts from Jurkat cells were 
prepared by lysing cells in 1X NuPAGE LDS sample buffer (26.5 mM Tris HCl [pH 8.5], 
35.25 mM Tris Base, 0.5% LDS, 2.5 % glycerol, 0.1275 mM EDTA). Protein samples were 
fractionated on 10% polyacrylamide gels, and transferred to PVDF membranes (Bio-Rad). 
Antibodies used in this study were directed against: p-eIF4E (Ser209) (#9741, Cell 
Signaling), eIF4E (#9742, Cell Signaling), p-ERK 1/2 (#9106, Cell Signaling), ERK 1/2 
(#9102, Cell Signaling), eEF2 (#2332, Cell Signaling), and GAPDH (ab8245, Abcam). 
SDS-1-021-(−), Roc A-(−), and Roc A-(+) were synthesized using biomimeic kinetic 
resolution of chiral, racemic aglain ketone precursors as recently published (25) followed by 
amide formation (26). Silvestrol and CR-1-31-B were synthesized as previously reported (9, 
27). The concentrations of compound used were based on our experience with this class of 
small molecules, as well as previously published studies (2, 5, 6, 9, 12).
Cell Labeling and TCA Precipitations
35S-methionine/cysteine protein labeling was performed as previously described (11). 
Essentially, the day prior to metabolic labeling, Jurkat cells were seeded at 500,000 cells/ml 
and NIH 3T3, Mnk1+/+Mnk2+/+, and Mnk1−/−Mnk2−/− MEFs were seeded at 250 
cells/mm2. On the day of labeling, cells were exposed to the indicated concentrations of 
rocaglates for 2 hours. During the last 30 minutes of incubation, [35S]-methionine/cysteine 
was added (150–200 μCi/ml; 1175 Ci/mmole) (Perkin Elmer, Waltham, MA) and the 
labeling reactions were terminated with the addition of RIPA lysis buffer (20 mM Tris [pH 
7.6], 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP40, 0.5% Sodium Deoxycholate, 
0.1% SDS, 1 mM PMSF, 4 μg/ml aprotinin, 2 μg/ml leupeptin, 2 μg/ml pepstatin). Lysates 
were then spotted onto 3 MM Whatman paper (1.5 cm2 squares) that had been preblocked 
with MEM Non-Essential Amino Acid mixture (Gibco). After drying, filters were 
submerged in ice-cold 10% trichloroacetic acid (TCA)/ 0.1% L-methionine for 20 minutes, 
followed by boiling in 5% TCA for 15 minutes. The Whatman squares were washed twice 
with cold 5% TCA and then twice more with 95% ethanol, with each wash lasting one 
minute. Filter squares were dried and the amount of radiolabelled precipitated protein was 
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quantitated by scintillation counting (Beckman Coulter). Counts were standardized to total 
protein content that had been previously determined using the DC protein assay (Bio-Rad).
RNA Binding assay
Body-labeled [32P]-labeled RNA was produced by in vitro transcription of pSP/CAT 
(linearized with PvuII) using SP6 RNA polymerase. Recombinant eIF4AI was purified as 
previously reported (28). Binding assays were performed by incubating [32P]-labeled RNA 
(35000 cpm) with recombinant eIF4AI in binding buffer (25 mM Tris [pH 7.5], 1 mM DTT, 
100 mM KCl, 1 mM ATP, 5 mM MgCl2) in the presence of 5 μM of the indicated 
compound or 0.1% DMSO for 10 minutes at 37 °C, as previously noted (9). No pre-
incubations were performed and when reactions were assembled rocaglates were added 
pentultimately before the addition of [32P]-labeled RNA. Reactions were terminated by the 
addition of 1 mL stop buffer (25 mM Tris [pH 7.5], 100 mM KCl, 3 mM MgCl2) and then 
filtered through nitrocellulose (45 μM HA Millipore) (preblocked with 0.1% sodium 
pyrophosphate). Filters were washed 3 times with 1 mL stop buffer, dried, and the amount 
of retained [32P]-labeled RNA quantitated by liquid scintillation counting.
RESULTS
Our previous work investigating the consequences of silvestrol (2, 5), CR-1-31-B [a.k.a. 
hydroxamate (−)-9] (9) and SDS-1-021-(−) (RC., unpublished observations) (Fig. 1B) on 
translation indicate that these compounds target eIF4A and prevent its entry/recycling into 
the eIF4F complex (Fig. 1A). Li-Weber and colleagues (17) have reported that rocaglates, 
such as RocA (Fig. 1B) can also inhibit PHB1/2 to downregulate ERK activation, although 
the downstream effects on eIF4E S209 phosphorylation were never reported. We therefore 
decided to investigate this potential relationship and also took the opportunity to synthesize 
enantio-enriched preparations of RocA to tease out possible biological differences between 
the stereoisomers (Fig. 1B).
To assess the relative potencies of the rocaglates on translation, we performed a series of 
titrations in Jurkat and NIH/3T3 cells and measured relative levels of protein synthesis using 
[35S]-methionine/cysteine metabolic labeling. To ensure that the measured values reflected 
the immediate effects of the compounds on translation, cells were exposed to the indicated 
rocaglate for only 2 hours, which was also the shortest incubation period used by Li-Weber 
and colleagues to assess translation inhibition (17). Concentrations tested ranged from 10 
nM to 100 nM, as rocaglates have been previously reported to be effective inhibitors of 
translation at nanomolar concentrations (2). Based on the relative IC50s, as defined by the 
concentration of compound required to inhibit translation by 50%, SDS-1-021-(−) was 
found to be the most potent rocaglate (IC50 < 10 nM) in Jurkat cells, followed by RocA-(−) 
and CR-1-31-B (Fig. 1C). In NIH/3T3 cells, SDS-1-021-(−) and CR-1-31-B showed similar 
potencies, with IC50s ~20 nM for translation inhibition under our test conditions (Fig. 1C). 
Silvestrol and RocA-(−) were slightly less potent with IC50s of ~50 nM. RocA-(+) did not 
inhibit translation in either cell line highlighting the importance of compound 
stereochemistry for biological activity, as previously noted (9). In sum, these results indicate 
that individual rocaglates exert differences in their ability to inhibit translation across cell 
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lines, as previously reported (5, 9), and that within this small series, SDS-1-021-(−) is the 
most potent compound tested (Fig. 1C).
RocA has been shown to inhibit ERK 1/2 phosphorylation in Jurkat cells (17), although its 
effects on eIF4E phosphorylation have never been reported. We found that, with the 
exception of RocA-(+), all other rocaglates suppressed ERK 1/2 phosphorylation in Jurkat 
cells (Fig. 2A). Silvestrol, CR-1-31-B, and SDS-1-021-(−) completely blocked 
phosphorylation and modest inhibition was observed at 100 nM RocA-(−) (Fig. 2A). 
Surprisingly, eIF4E phosphorylation was not inhibited and, contrary to expectations, was 
stimulated by CR-1-31-B and SDS-1-021-(−). In contrast, in NIH/3T3 cells we observed 
stimulation, not inhibition, of ERK 1/2 phosphorylation by all rocaglates tested, with the 
exception of the inactive RocA-(+) enantiomer, compared to vehicle-treated cells (Fig. 2B). 
None of the tested rocaglates affected phospho-eIF4E status in NIH/3T3 cells under the 
tested conditions. To exclude the possibility that the absence of diminished eIF4E 
phosphorylation is a consequence of low levels of MEK/ERK activity in NIH/3T3 cells, we 
transformed the cells with RAS in order to elevate ERK signaling and treated with the 
rocaglate series (Fig. 2C). All rocaglates tested stimulated p-ERK levels in RAS-
transformed NIH/3T3 cells with little effect on p-eIF4E status(Fig. 2C). This is consistent 
with what was noted in non-transformed NIH/3T3 cells and we have not further investigated 
the underlying molecular mechanism. Nonetheless, there is little correlation between ERK 
and eIF4E phosphorylation status with the inhibition of translation documented above (Fig. 
1C). One well-characterized activity of rocaglates is stimulation of the RNA-binding activity 
of eIF4A (2, 5, 9). To assess whether the rocaglate series under evaluation retained this 
activity, we performed RNA filter binding assays in vitro using 32P-labelled RNA in the 
presence of 5 μM of each compound, which is within the concentration range of silvestrol 
previously shown to stimulate RNA binding of eIF4A (2) (Fig. 2D). With the exception of 
the inactive RocA-(+) enantiomer, all rocaglates stimulated binding of eIF4A to RNA, with 
SDS-1-021-(−) being the most potent compound (Fig. 2D).
To further support the notion that eIF4E phosphorylation status is inconsequential to the 
inhibition of translation observed with rocaglates, we quantitated the effects of rocaglates on 
protein synthesis in Mnk1−/−Mnk2−/− MEFs, where eIF4E cannot be phosphorylated (Fig. 
3A) (29). Whereas we observed a slight difference in the sensitivities between 
Mnk1−/−Mnk2−/− and Mnk1+/+Mnk2+/+ MEFs (~40%) towards silvestrol, there was no 
significant difference on translation exerted by the other tested rocaglates in these two cell 
types (Fig. 3A). Consistent with our results in Jurkat and NIH/3T3 cells, SDS-1-021-(−) was 
the most potent inhibitor among the series tested (Fig. 3A). Western blots of extracts 
confirmed the complete absence of eIF4E phosphorylation in the Mnk1−/−Mnk2−/− MEFs as 
well as the absence of diminished eIF4E phosphorylation in Mnk1+/+Mnk2+/+ MEFs (Fig. 
3B). As a positive control, we included the Mnk1 inhibitor, CGP57380, and observed 
reduced phospho-eIF4E levels in Mnk1+/+Mnk2+/+ MEFs (Fig. 3B) (30).
DISCUSSION
In this study, we report that translation inhibition by rocaglates is independent of eIF4E 
phosphorylation status. Although we have not directly tested the ability of our rocaglate 
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series to inhibit PHB1/2:c-RAF association, RocA has been previously shown to block this 
interaction (17). We find that the effects of rocaglates on p-ERK 1/2 and p-eIF4E status 
appear cell-type dependent and overall do not correlate with rocaglate-induced translation 
inhibition (Fig. 2). It is clear that in the complete absence of eIF4E phosphorylation, the 
ability of CR-1-31-B, SDS-1-021-(−), and RocA-(−) to inhibit protein synthesis is 
unperturbed (Fig. 3). Silvestrol, but not CR-1-31-B, is a known Pgp-1 multi-drug transporter 
substrate (31) (R.C. and J.P., unpublished observations). Whether the increased sensitivity of 
Mnk1−/−Mnk2−/− cells to silvestrol is due to reduced expression of Pgp-1 and/or other drug 
response modifiers remains to be evaluated (Fig. 3A).
As reported by Li-Weber and colleagues (17), we also find that rocaglates inhibit ERK 1/2 
phosphorylation in Jurkat cells (Fig. 2A). However, in NIH/3T3 cells we observed 
stimulation, not inhibition, of this post-translational modification (Fig. 2B, C). The increase 
in p-eIF4E that we observed with the more potent SDS-1-021-(−) and CR-1-31-B 
compounds in Jurkat cells is unlinked to p-ERK 1/2 status and may reflect activation of a 
stress kinase response—an effect that has been previously documented with other translation 
inhibitors including anisomycin, onnamide A, and theopederin B (32, 33). This increase in 
p-eIF4E levels is contrary to what would be expected upon ERK 1/2 inhibition, which one 
would expect to stimulate, not inhibit, selective mRNA translation (20, 22–24).
Our results do not rule out the possibility that some rocaglate family members not tested 
here can block eIF4E phosphorylation given the appropriate context. Indeed, the compound 
RocAR has been reported to exhibit this activity in HTLV-infected ATL (adult T-cell 
leukemia/lymphoma) cells (34). However, our data indicate that this is not a general feature 
of this class of compounds, and that rocaglate-induced translation inhibition is independent 
of eIF4E phosphorylation status. Taken together with previous data indicating that these 
compounds also do not inhibit translation by increasing eIF2α phosphorylation (5), the 
consequences of rocaglates on translation appear best explained by their effects on eIF4A 
activity.
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Figure 1. 
A. Proposed mechanism of action of rocaglates on eIF4A recycling through the eIF4F 
complex. In this model, rocaglates stimulate eIF4A RNA binding, rendering it unavailable to 
enter into the eIF4F complex. B. Structures of rocaglates used in this study. C. Dose-
dependent inhibition of translation by rocaglates in Jurkat and NIH/3T3 cells. Cells were 
incubated in the presence of compound for a total of 2 hours and protein synthesis rates were 
determined as described in the Materials and Methods. The relative rates are of translation 
are calculated by normalizing to DMSO. n = 4; error bars represent the error of the mean.
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Figure 2. 
A. Effects of rocaglates on eIF4E phosphorylation in Jurkat cells. Cells were incubated in 
the presence of the indicated compounds for 2 hours, lysed, fractionated on a 10% NuPAGE 
Bis-Tris gel, and transferred to PVDF membranes for western blotting. Blots were probed 
using antibodies directed to the proteins indicated to the right of the panel. B. Effects of 
rocaglates on eIF4E phosphorylation status in NIH/3T3 cells. Cells were treated, proteins 
fractionated, transferred to PVDF membranes, and western blots analyzed as described for 
Panel A. C. Effects of rocaglates on eIF4E phosphorylation status in RAS-transformed 
NIH/3T3 cells. Cells were treated, proteins fractionated, transferred to PVDF membranes, 
and western blots analyzed as described for Panel A. The dashed line indicates that probing 
for eIF4E and ERK were performed on different membranes. GAPDH levels were used as 
an internal standard to account for variations in extract levels between lanes. D. Stimulation 
of eIF4A:RNA binding by rocaglates. Recombinant eIF4A (1.3 μM) was incubated with 35 
000 cpm of 32P-labelled RNA in the presence of 5 μM rocaglate and processed as described 
in the Materials and Methods. eIF4A:RNA complexes retained on nitrocellulose filters were 
quantitated by scintillation counting. N = 3; error bars represent error of the mean.
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Figure 3. 
A. Rocaglates inhibit translation in Mnk1+/+Mnk2+/+ and Mnk1−/−Mnk2−/− MEFs. Protein 
synthesis rates were determined as described in the Materials and Methods. The relative 
rates of 35S-Met incorporation are normalized to DMSO. N = 4; error bars represent error of 
the mean. *, p < 0.001 (Student's t-test). B. Effects of rocaglates on eIF4E phosphorylation 
in Mnk1+/+Mnk2+/+ and Mnk1−/−Mnk2−/− cells. Cells were incubated in the presence of the 
indicated compounds for two hours, lysed, fractionated on a 10% polyacrylamide gel, and 
transferred to PVDF membranes for western blotting. Blots were probed with antibodies 
directed to the proteins indicated to the right of the panel. GAPDH levels were used as an 
internal standard to account for variations in extract levels between lanes. Note that lane 24 
is slightly underloaded based on the GAPDH internal standard.
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